KRAS and lung carcinoma: Importantly, this combination produced potent tumour regressions in a series of KRAS-mutant lung cancer models in vivo, such as LSL-KRASG12D mouse model and PDTX models, as well as orthotopic lung cancer models (Fig. 5; Supplementary Fig. 3).